Key result
Rapid up-titration of GDMT to maximum tolerated doses improves HFrEF outcomes.
Why the study?
Simultaneous and rapid uptitration of HFrEF medications is critical to enhance outcomes, but clinicians encounter challenges such as hypotension, fatigue, worsening renal function, and hyperkalemia.
This review provides practical strategies for the simultaneous initiation and rapid up-titration of guideline-directed medical therapy in patients with HFrEF, addressing common clinical challenges.
Supports GDMT up-titration strategies in HFrEF; leaves open need for randomized confirmation.
With the increasing number of medications demonstrating mortality benefits in heart failure with reduced ejection fraction (HFrEF), the pharmacological treatment of HFrEF is entering a new phase. To enhance outcomes in heart failure patients through medical treatment, the choice of appropriate medications and simultaneous and rapid uptitration are critical. However, there are several challenges encountered during this medication uptitration, including issues like hypotension, fatigue, worsening renal function, and hyperkalemia. This paper addresses strategies for effectively managing these challenges to successfully reach the maximum tolerated dose in patients. Additionally, it will discuss the management of comorbidities often associated with heart failure, the importance of exercise and rehabilitation, and the significance of proper nutrition intake, in addition to guideline-directed medical therapy.
No takes yet. Share an insight, caveat, or question.
Bak et al. (2023) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Guideline-directed medical therapy (GDMT) was evaluated. Rapid up-titration of guideline-directed medical therapies to maximum tolerated doses is critical for improving outcomes in patients with heart failure with reduced ejection fraction.